前列腺素衍生物對睫狀體基底膜中laminin isomers分佈的影響
Date Issued
2002
Date
2002
Author(s)
王清泓
DOI
902314B002443
Abstract
Purpose: To investigate the long term safety and efficacy of latanoprost for chronic angle-closure glaucoma (CACG).
Patients and methods: The patients in both groups had the intraocular pressures (lOP) in the range of 20 to 35 mmHg after discontinuation of all antiglaucoma medications and the presence of glaucomatous optic neuropathy and/or visual filed defects. CACG was defined as the presence of more than 180 degree appositional closed anterior chamber angle and signs of peripheral anterior synechiae on Zeiss indentation gonioscopy. POAG was defined as a normal and open angle on gonioscopic examination. No previous ocular surgery and laser treatment was noted in all patients, except every CACG patient had received laser iridectomy. One drop of 0.005% latanoprost daily was the only treatment for every patient in the 24-month follow up period. Results: We enrolled 69 CACG patients (Male/Female: 17/52) with the age of 59.4¡Ó10.2 y/o. The baseline lOP was 24.3¡Ó3.4 mmHg. After 2-year follow up, the lOP was reduced from baseline by 6.6¡Ó1.2 mmHg (27.6¡Ó5.17%), and 63.8% had a reduction of lOP from baseline for more than 20%. The percentage of patients whose lOPs after treatment were not lower than baseline was 18.8%. The lOP after 2-yr treatment were significantly reduced from the baseline in both groups, however, there was no difference between CACG and POAG.
Conclusion: 0.005% latanoprost is an effective treatment for lOP reduction in both CACG patients.
Subjects
latanoprost
angle-closure glaucoma
Publisher
臺北市：國立臺灣大學醫學院眼科
Type
journal article
File(s)![Thumbnail Image]()
Loading...
Name
902314B002443.pdf
Size
669.05 KB
Format
Adobe PDF
Checksum
(MD5):b727e327b7e5da1e8d114955b2752216